FBLG Shares Plunge 22% on Reverse Stock Split Plan

FibroBiologics Announces 1-for-20 Reverse Stock Split

FibroBiologics Inc. (NASDAQ:FBLG) saw its shares fall 22.2% in after-hours trading following the announcement of a 1-for-20 reverse stock split. The company stated the move is intended to regain compliance with The Nasdaq Capital Market's minimum bid price requirement.

Situation Overview

The reverse stock split, approved by the Board of Directors and stockholders, is set to become effective on March 30, 2026. This action will consolidate every 20 shares of common stock into one share. Consequently, the number of outstanding shares will decrease from approximately 70.26 million to about 3.51 million.

Impact on Shareholders and Market

The immediate market reaction was negative, reflecting investor sentiment towards the stock consolidation. However, the reverse split will not alter any stockholder’s percentage ownership interest, aside from adjustments for fractional shares which will be rounded up. The split will also proportionately adjust the company’s equity incentive plans and outstanding equity awards.

Summary

While the reverse split is a necessary step for maintaining its Nasdaq listing, the focus for investors will shift to the company's long-term operational performance. The new CUSIP number for the company’s common stock following the split will be 31573L204. VStock Transfer, LLC, will act as the exchange agent for the process.

FAQ

Q: Why did FibroBiologics implement a reverse stock split?
A: The primary goals are to regain compliance with Nasdaq's minimum bid price rule and to broaden potential investor interest.

Q: How does the reverse split affect an individual shareholder?
A: A shareholder's percentage of ownership in the company remains unchanged, although they will hold fewer, but proportionally more valuable, shares.

Source: Investing.com